Piyush Goyal Chairs Roundtable to Strengthen India's Biopharma Startup Ecosystem

Commerce Minister Piyush Goyal has called for stronger startup support, faster regulatory approvals and improved infrastructure to accelerate India's biopharma sector and expand its bioeconomy.

Piyush Goyal Chairs Roundtable to Strengthen India's Biopharma Startup Ecosystem and Bioeconomy

Union Minister of Commerce and Industry Piyush Goyal has chaired a high-level roundtable discussion aimed at strengthening India's biopharma startup ecosystem and accelerating the country's bioeconomy growth. The meeting, titled India's Bioeconomy Opportunity: Role of Startups in Driving Innovation and Growth, was held at Vanijya Bhawan in New Delhi.

The Department for Promotion of Industry and Internal Trade (DPIIT) organised the roundtable in collaboration with NITI Aayog and the NITI Frontier Tech Hub. Policymakers, industry representatives and biopharma startup founders participated in discussions on creating a stronger environment for innovation, investment and business expansion.

During the meeting, Goyal highlighted the importance of India's scientific expertise and entrepreneurial capabilities in establishing the country as a global leader in the bioeconomy.

Piyush Goyal Calls for Stronger Support for Biopharma Startups

Addressing the participants, Piyush Goyal emphasised the need to create a supportive ecosystem that enables Indian startups to transform scientific research into commercially successful innovations.

He highlighted several priority areas that require attention, including faster regulatory approvals, easier access to funding, common research infrastructure and stronger cooperation between industry, academic institutions and government bodies.

The minister also stressed the importance of implementing recommendations emerging from the roundtable within a defined timeline.

The discussions focused on ensuring that promising startups receive the necessary institutional and financial support to develop innovative products and compete in international markets.

Faster Regulatory Approvals and Simplified Business Processes

One of the major topics discussed during the roundtable was the need to simplify regulatory procedures for biopharma startups.

Participants highlighted how lengthy approval processes and complicated compliance requirements can increase operational costs and delay the commercialisation of new technologies.

To address these challenges, the discussions covered several proposed measures:

• Streamlining regulatory requirements and approval procedures.

• Introducing a proposed Regulatory Sandbox.

• Establishing a Single Window Clearance mechanism.

• Simplifying patent application processes.

• Improving coordination between government departments.

These measures are intended to create a more predictable business environment and help startups bring innovative products to market more efficiently.

Biopharma SHAKTI to Support India's Bioeconomy Ambitions

The roundtable also discussed the importance of Biopharma SHAKTI, which was announced in the Union Budget for FY27.

The initiative featured in discussions on strengthening India's biopharmaceutical capabilities and supporting the development of a competitive domestic ecosystem.

Participants highlighted the importance of connecting research institutions, startups and established companies to accelerate innovation and expand indigenous manufacturing capabilities.

The broader objective is to strengthen India's life sciences sector and improve its ability to develop and manufacture advanced biopharmaceutical products.

Shared Laboratories and Clinical Trial Facilities for Startups

Access to research infrastructure emerged as another important issue during the discussions.

Biopharma startups often require expensive laboratory equipment, specialised testing facilities and clinical trial infrastructure to develop and validate their products. Establishing these facilities independently can create significant financial challenges, particularly for early-stage businesses.

Participants therefore emphasised the need to develop shared laboratories, testing centres and clinical trial facilities.

Such common infrastructure could help startups reduce research and development expenses, improve access to specialised resources and accelerate the development of new technologies.

NITI Aayog Highlights Industry-Academia Collaboration

Distinguished Fellow at NITI Aayog, Debjani Ghosh, highlighted the importance of collaboration between startups, established industries, academic institutions and government organisations.

She emphasised that stronger partnerships among these stakeholders would be essential for developing an internationally competitive bioeconomy.

Member of NITI Aayog, Professor Gobardhan Das, stressed the importance of converting scientific discoveries into commercially viable products.

His remarks highlighted the need to bridge the gap between laboratory research and market-ready innovations so that scientific advancements can generate economic value.

Government Focuses on Indigenous Life Sciences Manufacturing

Participants also discussed measures to strengthen India's domestic life sciences manufacturing ecosystem.

Key recommendations included improving access to imported laboratory equipment and research materials by expediting customs clearance for essential equipment and reagents.

Better coordination between different ministries and government departments was also identified as an important requirement.

These steps could help reduce administrative delays, improve research efficiency and support the expansion of domestic manufacturing capabilities.

India's Bioeconomy: Focus on Innovation and Global Competitiveness

The roundtable reflects India's broader efforts to position its bioeconomy as an important driver of economic growth, scientific innovation and industrial development.

By improving access to finance, simplifying regulations and expanding shared research infrastructure, the government aims to create better opportunities for biopharma startups.

Stronger collaboration between industry, academia and policymakers could also help transform India's scientific capabilities into globally competitive products and technologies.

Conclusion

Piyush Goyal's roundtable on India's bioeconomy highlights the government's focus on building a stronger biopharma startup ecosystem through regulatory reforms, improved funding access and shared research infrastructure. With initiatives such as Biopharma SHAKTI and greater industry-academia collaboration, India aims to strengthen indigenous life sciences manufacturing, accelerate innovation and establish itself as a globally competitive bioeconomy.